NMUR2

Summary

NMUR2 (neuromedin U receptor 2, HGNC:16454) is a protein-coding gene on chromosome 5q33.1, encoding Neuromedin-U receptor 2 (Q9GZQ4). Receptor for the neuromedin-U and neuromedin-S neuropeptides.

This gene encodes a protein from the G-protein coupled receptor 1 family. This protein is a receptor for neuromedin U, which is a neuropeptide that is widely distributed in the gut and central nervous system. This receptor plays an important role in the regulation of food intake and body weight.

Source: NCBI Gene 56923 — RefSeq curated summary.

At a glance

• GWAS associations: 27
• Clinical variants (ClinVar): 63 total
• Druggable target: yes — 1 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_020167

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16454
Approved symbol	NMUR2
Name	neuromedin U receptor 2
Location	5q33.1
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000132911
Ensembl biotype	protein_coding
OMIM	605108
Entrez	56923

Gene structure

Transcript identifiers

Ensembl transcripts: 3 — 2 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000255262, ENST00000518933, ENST00000916655

RefSeq mRNA: 1 — MANE Select: NM_020167 NM_020167

CCDS: CCDS4321

Canonical transcript exons

ENST00000255262 — 4 exons

Exon	Start	End
ENSE00000767902	152395459	152395584
ENSE00001021222	152391546	152392501
ENSE00001021223	152404388	152405279
ENSE00003468312	152398060	152398144

Expression profiles

Bgee: expression breadth broad, 85 present calls, max score 82.48.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.1031 / max 15.2250, expressed in 36 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
64445	0.0539	19
64446	0.0492	21

Top tissues by expression

226 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
tibialis anterior	UBERON:0001385	82.48	silver quality
pancreatic ductal cell	CL:0002079	78.52	silver quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	78.23	gold quality
ileal mucosa	UBERON:0000331	78.10	silver quality
oocyte	CL:0000023	64.98	gold quality
deltoid	UBERON:0001476	63.25	silver quality
corpus callosum	UBERON:0002336	62.09	gold quality
upper leg skin	UBERON:0004262	57.64	gold quality
endothelial cell	CL:0000115	57.01	gold quality
epithelial cell of pancreas	CL:0000083	56.90	gold quality
myocardium	UBERON:0002349	56.26	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	56.23	gold quality
spinal cord	UBERON:0002240	54.76	gold quality
medial globus pallidus	UBERON:0002477	54.60	silver quality
cardiac muscle of right atrium	UBERON:0003379	54.34	gold quality
left ventricle myocardium	UBERON:0006566	54.23	gold quality
kidney epithelium	UBERON:0004819	53.93	gold quality
upper arm skin	UBERON:0004263	53.52	gold quality
right testis	UBERON:0004534	52.47	gold quality
quadriceps femoris	UBERON:0001377	52.42	gold quality
right lung	UBERON:0002167	51.44	gold quality
hypothalamus	UBERON:0001898	50.77	gold quality
sperm	CL:0000019	50.74	gold quality
left testis	UBERON:0004533	50.34	gold quality
testis	UBERON:0000473	50.14	gold quality
vastus lateralis	UBERON:0001379	49.88	gold quality
right lobe of thyroid gland	UBERON:0001119	48.65	gold quality
Brodmann (1909) area 9	UBERON:0013540	47.96	gold quality
Brodmann (1909) area 46	UBERON:0006483	47.86	gold quality
left lobe of thyroid gland	UBERON:0001120	47.71	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	3.90

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

57 targeting NMUR2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3064-3P	100.00	70.09	1254
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-450A-1-3P	100.00	69.33	1837
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-454-3P	99.91	74.01	1925
HSA-MIR-106A-5P	99.90	73.94	2683
HSA-MIR-374A-5P	99.90	71.34	2923
HSA-MIR-374B-5P	99.90	69.98	2734
HSA-MIR-130A-3P	99.90	73.31	1861
HSA-MIR-130B-3P	99.90	73.27	1850
HSA-MIR-301A-3P	99.90	73.15	1839
HSA-MIR-301B-3P	99.90	73.19	1836
HSA-MIR-3666	99.90	73.24	1833
HSA-MIR-4295	99.90	73.11	1838
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-17-5P	99.89	73.83	2665
HSA-MIR-106B-5P	99.88	74.72	2795
HSA-MIR-20A-5P	99.88	74.76	2769
HSA-MIR-20B-5P	99.88	74.01	2621
HSA-MIR-519D-3P	99.88	73.97	2607
HSA-MIR-526B-3P	99.88	74.06	2587
HSA-MIR-93-5P	99.88	73.98	2606
HSA-MIR-548AZ-5P	99.83	69.94	3230
HSA-MIR-548T-5P	99.83	69.91	3220
HSA-MIR-6817-3P	99.79	68.35	2126
HSA-MIR-34B-5P	99.78	67.56	1175
HSA-MIR-449C-5P	99.78	67.63	1168
HSA-MIR-2682-5P	99.73	67.38	1055
HSA-MIR-519A-3P	99.67	71.67	1868
HSA-MIR-519B-3P	99.67	71.67	1868

Literature-anchored findings (GeneRIF, showing 6)

• A cell-based reporter gene assay has been developed and used for the screening of the human NMU2R agonist. (PMID:16781063)
• polymorphisms in the gene may be useful in identifying women at risk for osteoporosis. (PMID:25871004)
• Study identified a novel NMUR2 splice variant lacking the third exon and able to form heteromeric complexes with NMUR1 and NMUR2 without Neuromedin U (NMU). Its expression can block NMU signaling suppressing then ovarian cancer cells proliferation. (PMID:26317338)
• NMU might contribute to progression of NMUR2-positive breast cancer (PMID:28423716)
• Activation by NMU2 is longer lasting if NmS is the ligand. (PMID:29724789)
• A genome-wide association study implicates the pleiotropic effect of NMUR2 on asthma and COPD. (PMID:36543808)

Cross-species orthologs

8 orthologs

Organism	Symbol	Gene ID
mus_musculus	Nmur2	ENSMUSG00000037393
rattus_norvegicus	Nmur2	ENSRNOG00000014081
drosophila_melanogaster	CapaR	FBGN0037100
drosophila_melanogaster	PK2-R2	FBGN0038139
drosophila_melanogaster	PK2-R1	FBGN0038140
drosophila_melanogaster	PK1-R	FBGN0038201
caenorhabditis_elegans		WBGENE00016747
caenorhabditis_elegans		WBGENE00019616

Paralogs (15): NTSR1 (ENSG00000101188), BRS3 (ENSG00000102239), MLNR (ENSG00000102539), GHSR (ENSG00000121853), GRPR (ENSG00000126010), NMBR (ENSG00000135577), EDNRB (ENSG00000136160), EDNRA (ENSG00000151617), NTSR2 (ENSG00000169006), GPR37L1 (ENSG00000170075), GPR37 (ENSG00000170775), NMUR1 (ENSG00000171596), GPR148 (ENSG00000173302), TRHR (ENSG00000174417), GPR39 (ENSG00000183840)

Protein

Protein identifiers

Neuromedin-U receptor 2 — Q9GZQ4 (reviewed: Q9GZQ4)

Alternative names: G-protein coupled receptor FM-4, G-protein coupled receptor TGR-1

All UniProt accessions (1): Q9GZQ4

UniProt curated annotations — full annotation on UniProt →

Function. Receptor for the neuromedin-U and neuromedin-S neuropeptides.

Subcellular location. Cell membrane.

Tissue specificity. Predominantly expressed in the CNS, particularly in the medulla oblongata, pontine reticular formation, spinal cord, and thalamus. High level in testis whereas lower levels are present in a variety of peripheral tissues including the gastrointestinal tract, genitourinary tract, liver, pancreas, adrenal gland, thyroid gland, lung, trachea, spleen and thymus.

Similarity. Belongs to the G-protein coupled receptor 1 family.

RefSeq proteins (1): NP_064552* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000276	GPCR_Rhodpsn	Family
IPR005390	NeuromedU_rcpt	Family
IPR005392	NeuromedU_rcpt_2	Family
IPR017452	GPCR_Rhodpsn_7TM	Domain
IPR045561	NMU-R2_C	Domain

Pfam: PF00001, PF19285

UniProt features (43 total): helix 12, topological domain 8, transmembrane region 7, sequence variant 5, strand 4, glycosylation site 3, chain 1, disulfide bond 1, sequence conflict 1, turn 1

Structure

Experimental structures (PDB)

3 structures.

PDB	Method	Resolution (Å)
7W55	ELECTRON MICROSCOPY	2.8
7W57	ELECTRON MICROSCOPY	3.2
7XK8	ELECTRON MICROSCOPY	3.3

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9GZQ4-F1	79.92	0.51

Antibody-complex structures (SAbDab): 2 — 7W55, 7W57

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (1): 119–204

Glycosylation sites (3): 9, 27, 194

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-375276	Peptide ligand-binding receptors
R-HSA-416476	G alpha (q) signalling events
R-HSA-418594	G alpha (i) signalling events

MSigDB gene sets: 106 (showing top): GOBP_BEHAVIOR, GOBP_REGULATION_OF_CALCIUM_MEDIATED_SIGNALING, GOBP_RESPONSE_TO_DIETARY_EXCESS, GOBP_REGULATION_OF_SMOOTH_MUSCLE_CONTRACTION, GOBP_INORGANIC_ANION_TRANSPORT, GOBP_MULTICELLULAR_ORGANISMAL_RESPONSE_TO_STRESS, GOBP_CELL_CELL_SIGNALING, GOBP_ORGANIC_ACID_TRANSPORT, REACTOME_PEPTIDE_LIGAND_BINDING_RECEPTORS, GOBP_POSITIVE_REGULATION_OF_CALCIUM_MEDIATED_SIGNALING, GOBP_EATING_BEHAVIOR, GOBP_REGULATION_OF_MUSCLE_CONTRACTION, GOBP_CHLORIDE_TRANSPORT, GOBP_MUSCLE_CONTRACTION, GOBP_RESPONSE_TO_PAIN

GO Biological Process (15): reduction of food intake in response to dietary excess (GO:0002023), regulation of smooth muscle contraction (GO:0006940), phospholipase C-activating G protein-coupled receptor signaling pathway (GO:0007200), neuropeptide signaling pathway (GO:0007218), cell-cell signaling (GO:0007267), central nervous system development (GO:0007417), grooming behavior (GO:0007625), feeding behavior (GO:0007631), response to pain (GO:0048265), arachidonate secretion (GO:0050482), positive regulation of calcium-mediated signaling (GO:0050850), chloride transport (GO:0006821), signal transduction (GO:0007165), G protein-coupled receptor signaling pathway (GO:0007186), chloride transmembrane transport (GO:1902476)

GO Molecular Function (7): neuromedin U receptor activity (GO:0001607), G protein-coupled receptor activity (GO:0004930), intracellularly calcium-gated chloride channel activity (GO:0005229), GTP binding (GO:0005525), neuropeptide receptor activity (GO:0008188), neuromedin U binding (GO:0042924), protein binding (GO:0005515)

GO Cellular Component (2): plasma membrane (GO:0005886), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
GPCR downstream signalling	2
Class A/1 (Rhodopsin-like receptors)	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
G protein-coupled receptor signaling pathway	3
cell communication	2
signaling	2
behavior	2
neuropeptide binding	2
response to dietary excess	1
eating behavior	1
regulation of muscle contraction	1
smooth muscle contraction	1
phospholipase C activator activity	1
nervous system development	1
system development	1
multicellular organismal response to stress	1
icosanoid secretion	1
arachidonate transport	1
calcium-mediated signaling	1
regulation of calcium-mediated signaling	1
positive regulation of intracellular signal transduction	1
monoatomic anion transport	1
inorganic anion transport	1
cellular process	1
regulation of cellular process	1
cellular response to stimulus	1
G protein-coupled receptor activity	1
signal transduction	1
chloride transport	1
monoatomic anion transmembrane transport	1
neuropeptide receptor activity	1
neuromedin U binding	1
transmembrane signaling receptor activity	1
chloride channel activity	1
ligand-gated monoatomic anion channel activity	1
intracellularly calcium-gated channel activity	1
guanyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
neuropeptide signaling pathway	1
G protein-coupled peptide receptor activity	1
binding	1
membrane	1
cell periphery	1

Protein interactions and networks

STRING

830 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
NMUR2	NMU	P48645	999
NMUR2	NMS	Q5H8A3	978
NMUR2	CHRNB4	P30926	559
NMUR2	GALNT10	Q86SR1	473
NMUR2	POMC	P01189	470
NMUR2	MPP2	Q14168	462
NMUR2	NPS	P0C0P6	446
NMUR2	DLG2	Q15700	443
NMUR2	AUTS2	Q8WXX7	435
NMUR2	VPS54	Q9P1Q0	419
NMUR2	PTPRD	P23468	415
NMUR2	CFDP1	Q9UEE9	411
NMUR2	HSD17B2	P37059	403
NMUR2	PPT1	P50897	397
NMUR2	NMUR1	Q9HB89	393

IntAct

24 interactions, top by confidence:

A	B	Type	Score
NMUR2		psi-mi:“MI:0915”(physical association)	0.560
TCF4	NMUR2	psi-mi:“MI:0915”(physical association)	0.560
NMUR2	TRAF2	psi-mi:“MI:0915”(physical association)	0.560
ADAMTSL4	NMUR2	psi-mi:“MI:0915”(physical association)	0.560
NMUR2	ADAMTSL4	psi-mi:“MI:0915”(physical association)	0.560
NMUR2	TCF4	psi-mi:“MI:0915”(physical association)	0.560
TRAF2	NMUR2	psi-mi:“MI:0915”(physical association)	0.560
NMUR2	NOTCH2NLA	psi-mi:“MI:0915”(physical association)	0.490
NOTCH2NLA	NMUR2	psi-mi:“MI:0915”(physical association)	0.490
RAMP1	NMUR2	psi-mi:“MI:0915”(physical association)	0.400
RAMP3	NMUR2	psi-mi:“MI:0915”(physical association)	0.400
NMUR2	RAMP1	psi-mi:“MI:0915”(physical association)	0.400
NMUR2	RAMP2	psi-mi:“MI:0915”(physical association)	0.400
NMUR2	TMEM63A	psi-mi:“MI:0914”(association)	0.350
NMUR2	SMPD2	psi-mi:“MI:0914”(association)	0.350

BioGRID (43): NMUR2 (Two-hybrid), NMUR2 (Two-hybrid), NMUR2 (Two-hybrid), KRTAP13-1 (Two-hybrid), NOTCH2NL (Two-hybrid), TAOK2 (Affinity Capture-MS), SLC6A6 (Affinity Capture-MS), SLC12A6 (Affinity Capture-MS), IGHA2 (Affinity Capture-MS), ATP2B4 (Affinity Capture-MS), TYW1 (Affinity Capture-MS), TMEM63A (Affinity Capture-MS), SLC41A3 (Affinity Capture-MS), ADCK2 (Affinity Capture-MS), ATP11C (Affinity Capture-MS)

ESM2 similar proteins: A0A2L0VBG2, A1ZAX0, B2ZHY2, O43194, O43614, O46635, O46639, O54798, O62809, O93603, O97967, P08909, P14842, P18599, P20789, P21761, P28223, P28335, P30975, P32247, P32940, P34968, P34981, P35363, P35371, P41984, P47751, P50128, P50129, P56490, P56719, P58308, Q01717, Q28596, Q4V622, Q5IS53, Q5IS66, Q5IS98, Q5R4Q6, Q5U431

Diamond homologs: A5A4K9, A5A4L1, C3ZQF9, O08725, O17239, O42179, O43193, O55040, O88319, O93603, P19020, P20789, P20905, P21917, P24628, P30989, P35367, P49683, P58826, P79291, Q09388, Q25188, Q28553, Q58CW4, Q5QD24, Q63384, Q7JQF1, Q8BZ39, Q8ITC7, Q90WY4, Q923Y8, Q92847, Q93126, Q95254, Q99P50, Q9ESQ4, Q9GZQ4, Q9HB89, Q9JJI5, Q9JJS7

SIGNOR signaling

10 interactions.

A	Effect	B	Mechanism
NMS	up-regulates	NMUR2	binding
NMUR2	“up-regulates activity”	GNAI1	binding
NMUR2	“up-regulates activity”	GNAI3	binding
NMUR2	“up-regulates activity”	GNAO1	binding
NMUR2	“up-regulates activity”	GNAZ	binding
NMUR2	“up-regulates activity”	GNAQ	binding
NMUR2	“up-regulates activity”	GNA14	binding
NMUR2	“up-regulates activity”	GNA15	binding
NMUR2	“up-regulates activity”	GNA12	binding
VXJPSOQJNUZHDN-YJFQKBDPSA-N	“up-regulates activity”	NMUR2	“chemical activation”

Disease & clinical

Clinical variants and AI predictions

ClinVar

63 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	54
Likely benign	4
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

737 predictions. Top by Δscore:

Variant	Effect	Δscore
5:152398058:A:AC	donor_gain	1.0000
5:152398059:C:CC	donor_gain	1.0000
5:152398059:CA:C	donor_gain	1.0000
5:152398059:CACAG:C	donor_gain	1.0000
5:152404380:ATACT:A	donor_loss	1.0000
5:152404381:TACT:T	donor_loss	1.0000
5:152404382:AC:A	donor_loss	1.0000
5:152404384:TCA:T	donor_loss	1.0000
5:152404385:CAC:C	donor_loss	1.0000
5:152404386:A:AC	donor_gain	1.0000
5:152404386:A:T	donor_loss	1.0000
5:152404386:ACT:A	donor_gain	1.0000
5:152404387:C:CT	donor_gain	1.0000
5:152404387:CT:C	donor_gain	1.0000
5:152404387:CTC:C	donor_gain	1.0000
5:152404387:CTCT:C	donor_gain	1.0000
5:152404387:CTCTG:C	donor_gain	1.0000
5:152395582:CAA:C	acceptor_gain	0.9900
5:152395585:C:CC	acceptor_gain	0.9900
5:152398141:TTAGC:T	acceptor_loss	0.9800
5:152398142:TAG:T	acceptor_gain	0.9800
5:152398142:TAGC:T	acceptor_loss	0.9800
5:152398143:AGC:A	acceptor_loss	0.9800
5:152398144:GCT:G	acceptor_loss	0.9800
5:152398145:C:A	acceptor_loss	0.9800
5:152398145:C:CC	acceptor_gain	0.9800
5:152398146:T:G	acceptor_loss	0.9800
5:152404379:GATAC:G	donor_loss	0.9800
5:152404492:TGATG:T	donor_gain	0.9800
5:152398051:GGCAC:G	donor_loss	0.9700

AlphaMissense

2741 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
5:152404691:G:C	S141R	0.996
5:152404691:G:T	S141R	0.996
5:152404693:T:G	S141R	0.996
5:152404856:G:C	S86R	0.996
5:152404856:G:T	S86R	0.996
5:152404858:T:G	S86R	0.996
5:152395533:C:G	R288P	0.993
5:152395544:G:C	F284L	0.990
5:152395544:G:T	F284L	0.990
5:152395546:A:G	F284L	0.990
5:152404758:C:G	C119S	0.990
5:152404759:A:T	C119S	0.990
5:152404706:G:C	S136R	0.989
5:152404706:G:T	S136R	0.989
5:152404708:T:G	S136R	0.989
5:152404603:A:G	W171R	0.988
5:152404603:A:T	W171R	0.988
5:152404759:A:G	C119R	0.988
5:152404503:C:G	C204S	0.987
5:152404504:A:T	C204S	0.987
5:152404504:A:G	C204R	0.986
5:152392482:G:C	S319R	0.984
5:152392482:G:T	S319R	0.984
5:152392484:T:G	S319R	0.984
5:152404683:C:G	R144P	0.984
5:152404778:G:C	F112L	0.984
5:152404778:G:T	F112L	0.984
5:152404780:A:G	F112L	0.984
5:152395520:G:C	S292R	0.983
5:152395520:G:T	S292R	0.983

dbSNP variants (sampled 300 via entrez): RS1000565906 (5:152405805 C>T), RS1000622662 (5:152401416 T>A,C), RS1000895609 (5:152395068 A>G,T), RS1000914600 (5:152406779 GT>G), RS1001345424 (5:152395166 G>A,T), RS1001504932 (5:152405507 T>C), RS1001578682 (5:152398657 G>C,T), RS1001620970 (5:152392070 C>A), RS1001900930 (5:152393771 G>A,T), RS1001928911 (5:152400350 T>G), RS1001930097 (5:152393832 G>A,T), RS1001966684 (5:152399792 A>G), RS1002154351 (5:152406044 G>A), RS1002580312 (5:152397325 C>T), RS1002632399 (5:152397103 T>A)

Disease associations

OMIM: gene MIM:605108 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

27 associations (top):

Study	Trait	p-value
GCST000659_1	Optic nerve measurement (cup area)	8.000000e-06
GCST001567_9	Bipolar disorder and schizophrenia	7.000000e-06
GCST002136_12	Periodontitis (PAL4Q3)	5.000000e-06
GCST002932_22	Manganese levels	2.000000e-07
GCST003766_70	Subjective well-being	2.000000e-08
GCST004946_41	Schizophrenia	4.000000e-08
GCST006913_6	Sedentary behaviour duration	2.000000e-08
GCST006919_3	Ability to confide in someone	4.000000e-06
GCST006923_1	Loneliness	1.000000e-07
GCST006923_12	Loneliness	8.000000e-10
GCST006924_10	Loneliness (MTAG)	8.000000e-09
GCST006942_3	Feeling lonely	6.000000e-09
GCST007326_103	Number of sexual partners	1.000000e-11
GCST007565_181	Morning person	6.000000e-14
GCST007565_4	Morning person	2.000000e-17
GCST007565_5	Morning person	2.000000e-18
GCST007565_66	Morning person	9.000000e-14
GCST007565_72	Morning person	7.000000e-18
GCST007565_9	Morning person	4.000000e-18
GCST007576_29	Chronotype	2.000000e-18
GCST009391_1228	Metabolite levels	8.000000e-06
GCST009391_1894	Metabolite levels	3.000000e-06
GCST010397_33	Gut microbiota (bacterial taxa, rank normal transformation method)	2.000000e-06
GCST010988_344	Adult body size	3.000000e-09
GCST010989_255	Body size at age 10	2.000000e-10
GCST011124_18	Caffeine consumption from tea	1.000000e-10
GCST011767_8	Bipolar disorder	5.000000e-09

EFO canonical traits (10, from GWAS)

EFO ID	Trait name
EFO:0007869	wellbeing measurement
EFO:0008002	physical activity measurement
EFO:0009592	social interaction measurement
EFO:0007865	loneliness measurement
EFO:0008328	chronotype measurement
EFO:0010421	triacylglycerol 54:3 measurement
EFO:0010414	triacylglycerol 52:2 measurement
EFO:0007874	gut microbiome measurement
EFO:0009819	comparative body size at age 10, self-reported
EFO:0010091	tea consumption measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL1075144 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

1 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 57,988 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL226335	RUTIN	3	57,988

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: gpcr — Neuromedin U receptors

Most potent curated ligand interactions (18 total), top 18:

Ligand	Action	Affinity	Parameter
neuromedin U-25	Agonist	9.9	pKi
[125I]neuromedin U-25 (human)	Agonist	9.8	pKd
neuromedin U-23	Agonist	9.7	pKi
neuromedin U-25	Agonist	9.6	pKi
neuromedin U-8	Agonist	9.3	pKi
neuromedin S-33	Agonist	9.2	pIC50
[125I]neuromedin U-23 (rat)	Agonist	9.1	pKd
[125I]neuromedin U-8 (pig)	Agonist	9.1	pKd
HAS-NMU	Full agonist	9.0	pEC50
compound 6b [PMID: 24999562]	Full agonist	9.0	pEC50
NY0116	Agonist	8.77	pEC50
CPN-219	Agonist	8.66	pEC50
CPN-116	Agonist	8.19	pEC50
neuromedin U-8	Agonist	8.1	pKi
PEG40-NMU	Full agonist	8.0	pEC50
R-PSOP	Antagonist	7.04	pKB
NM4-C16	Full agonist	6.1	pIC50
compound NRA 4 [PMID: 25262941]	Full agonist	4.85	pEC50

ChEMBL bioactivities

178 potent at pChembl≥5 of 184 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
9.82	EC50	0.15	nM	CHEMBL4098010
9.80	EC50	0.16	nM	CHEMBL4081760
9.70	EC50	0.2	nM	CHEMBL4063341
9.70	EC50	0.2	nM	CHEMBL4074121
9.67	EC50	0.2138	nM	CHEMBL3758577
9.66	EC50	0.22	nM	CHEMBL4068681
9.55	EC50	0.28	nM	CHEMBL4088263
9.51	EC50	0.31	nM	CHEMBL4059530
9.47	EC50	0.3388	nM	CHEMBL3759452
9.47	EC50	0.34	nM	CHEMBL4061507
9.43	EC50	0.37	nM	CHEMBL4091611
9.41	EC50	0.39	nM	CHEMBL4087867
9.40	EC50	0.4	nM	CHEMBL3356083
9.39	EC50	0.41	nM	CHEMBL4073946
9.38	EC50	0.42	nM	CHEMBL4090300
9.37	EC50	0.43	nM	CHEMBL4079986
9.37	EC50	0.43	nM	CHEMBL3356083
9.33	EC50	0.47	nM	CHEMBL4063830
9.24	EC50	0.58	nM	CHEMBL4089636
9.24	EC50	0.57	nM	CHEMBL4097355
9.16	EC50	0.69	nM	CHEMBL4095998
9.15	EC50	0.7	nM	CHEMBL4177021
9.15	EC50	0.71	nM	CHEMBL4169726
9.13	EC50	0.74	nM	CHEMBL4100718
9.10	EC50	0.7943	nM	CHEMBL3315349
9.10	EC50	0.8	nM	CHEMBL4061906
9.09	EC50	0.82	nM	CHEMBL4099780
9.08	EC50	0.83	nM	CHEMBL4070175
9.08	EC50	0.83	nM	CHEMBL4172552
9.04	EC50	0.92	nM	CHEMBL3315349
9.03	EC50	0.94	nM	CHEMBL4071218
9.03	EC50	0.93	nM	CHEMBL4092033
8.92	EC50	1.2	nM	CHEMBL4060027
8.85	EC50	1.4	nM	CHEMBL4069256
8.82	EC50	1.5	nM	CHEMBL4083670
8.80	EC50	1.6	nM	CHEMBL4161902
8.77	IC50	1.7	nM	CHEMBL3356083
8.74	EC50	1.8	nM	CHEMBL4060830
8.74	EC50	1.8	nM	CHEMBL4169739
8.72	EC50	1.905	nM	CHEMBL4299242
8.72	EC50	1.9	nM	CHEMBL4092080
8.70	EC50	2	nM	CHEMBL4081819
8.70	IC50	2	nM	CHEMBL4169726
8.66	EC50	2.2	nM	CHEMBL4647192
8.62	IC50	2.4	nM	CHEMBL4177021
8.60	EC50	2.5	nM	CHEMBL3315349
8.59	EC50	2.6	nM	CHEMBL3425593
8.52	EC50	3	nM	CHEMBL4097408
8.48	EC50	3.3	nM	CHEMBL4088810
8.47	EC50	3.4	nM	CHEMBL4060571

PubChem BioAssay actives

182 with measured affinity, of 403 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-(3-aminopropanoylamino)-3-(4-hydroxyphenyl)propanoyl]amino]-3-phenylpropanoyl]amino]-3-methylbutanoyl]amino]-3-phenylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide	1446044: Agonist activity at human NMUR2 expressed in CHO cells assessed as induction of Ca2+ flux measured for 180 secs by Fluo 4-AM dye-based FLIPR assay	ec50	0.0001	uM
(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(2-amino-2-methylpropanoyl)amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide	1273140: Agonist activity at recombinant human NMU2 expressed in HEK293 cells assessed as change in intracellular calcium flux by fluorescence assay	ec50	0.0002	uM
(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-1-[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-3-(4-hydroxyphenyl)-2-[(2-piperazin-1-ylacetyl)amino]propanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]amino]butanediamide	1446044: Agonist activity at human NMUR2 expressed in CHO cells assessed as induction of Ca2+ flux measured for 180 secs by Fluo 4-AM dye-based FLIPR assay	ec50	0.0002	uM
(2S)-4-amino-2-[[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-1-[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-3-(4-hydroxyphenyl)-2-[(2-piperazin-1-ylacetyl)amino]propanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]amino]-4-oxobutanoic acid	1464657: Agonist activity at human NMUR2 expressed in CHO cells assessed as increase in intracellular calcium influx after 180 secs by Fluo 4-AM dye based FLIPR assay	ec50	0.0002	uM
(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-3-(4-hydroxyphenyl)-2-[(2-piperazin-1-ylacetyl)amino]propanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]pentanoyl]-methylamino]propanoyl]amino]pentanoyl]amino]butanediamide	1446044: Agonist activity at human NMUR2 expressed in CHO cells assessed as induction of Ca2+ flux measured for 180 secs by Fluo 4-AM dye-based FLIPR assay	ec50	0.0002	uM
(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-1-[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-3-(4-hydroxyphenyl)-2-[(2-piperazin-1-ylacetyl)amino]propanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]amino]butanediamide	1446044: Agonist activity at human NMUR2 expressed in CHO cells assessed as induction of Ca2+ flux measured for 180 secs by Fluo 4-AM dye-based FLIPR assay	ec50	0.0002	uM
(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide	1273140: Agonist activity at recombinant human NMU2 expressed in HEK293 cells assessed as change in intracellular calcium flux by fluorescence assay	ec50	0.0003	uM
(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-3-cyclohexyl-2-[[(2S)-3-(4-hydroxyphenyl)-2-[(2-piperazin-1-ylacetyl)amino]propanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide	1446044: Agonist activity at human NMUR2 expressed in CHO cells assessed as induction of Ca2+ flux measured for 180 secs by Fluo 4-AM dye-based FLIPR assay	ec50	0.0003	uM
(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-(3-aminopropanoylamino)-3-(4-hydroxyphenyl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-3-pyridin-4-ylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide	1446044: Agonist activity at human NMUR2 expressed in CHO cells assessed as induction of Ca2+ flux measured for 180 secs by Fluo 4-AM dye-based FLIPR assay	ec50	0.0003	uM
(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-(3-aminopropanoylamino)-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide	1446044: Agonist activity at human NMUR2 expressed in CHO cells assessed as induction of Ca2+ flux measured for 180 secs by Fluo 4-AM dye-based FLIPR assay	ec50	0.0003	uM
(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide	1446044: Agonist activity at human NMUR2 expressed in CHO cells assessed as induction of Ca2+ flux measured for 180 secs by Fluo 4-AM dye-based FLIPR assay	ec50	0.0004	uM
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-(3-aminopropanoylamino)-3-(4-hydroxyphenyl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide	1446044: Agonist activity at human NMUR2 expressed in CHO cells assessed as induction of Ca2+ flux measured for 180 secs by Fluo 4-AM dye-based FLIPR assay	ec50	0.0004	uM
(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-6-aminohexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide	1446044: Agonist activity at human NMUR2 expressed in CHO cells assessed as induction of Ca2+ flux measured for 180 secs by Fluo 4-AM dye-based FLIPR assay	ec50	0.0004	uM
(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-(3-aminopropanoylamino)-3-(4-hydroxyphenyl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide	1446044: Agonist activity at human NMUR2 expressed in CHO cells assessed as induction of Ca2+ flux measured for 180 secs by Fluo 4-AM dye-based FLIPR assay	ec50	0.0004	uM
(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-(3-aminopropanoylamino)-3-(4-hydroxyphenyl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide	1446044: Agonist activity at human NMUR2 expressed in CHO cells assessed as induction of Ca2+ flux measured for 180 secs by Fluo 4-AM dye-based FLIPR assay	ec50	0.0004	uM
(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-(3-aminopropanoylamino)-3-(4-hydroxyphenyl)propanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide	1446044: Agonist activity at human NMUR2 expressed in CHO cells assessed as induction of Ca2+ flux measured for 180 secs by Fluo 4-AM dye-based FLIPR assay	ec50	0.0004	uM
(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-(3-aminopropanoylamino)-3-(4-hydroxyphenyl)propanoyl]amino]-3-cyclohexylpropanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide	1446044: Agonist activity at human NMUR2 expressed in CHO cells assessed as induction of Ca2+ flux measured for 180 secs by Fluo 4-AM dye-based FLIPR assay	ec50	0.0005	uM
(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-(3-aminopropanoylamino)-3-(4-hydroxyphenyl)propanoyl]amino]-3-cyclohexylpropanoyl]amino]-3-methylbutanoyl]amino]-3-phenylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide	1446044: Agonist activity at human NMUR2 expressed in CHO cells assessed as induction of Ca2+ flux measured for 180 secs by Fluo 4-AM dye-based FLIPR assay	ec50	0.0006	uM
(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-(3-aminopropanoylamino)-3-(4-hydroxyphenyl)propanoyl]amino]-3-cyclohexylpropanoyl]amino]-4-methylpentanoyl]amino]-3-pyridin-4-ylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide	1446044: Agonist activity at human NMUR2 expressed in CHO cells assessed as induction of Ca2+ flux measured for 180 secs by Fluo 4-AM dye-based FLIPR assay	ec50	0.0006	uM
(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide	1352034: Agonist activity at human NMUR2 expressed in HEK293 cells assessed as induction of IP3 levels using myo-[2-3H(N)]-inositol after 60 mins by SPA-based topcount assay	ec50	0.0007	uM
(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-(3-aminopropanoylamino)-3-(4-hydroxyphenyl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide	1446044: Agonist activity at human NMUR2 expressed in CHO cells assessed as induction of Ca2+ flux measured for 180 secs by Fluo 4-AM dye-based FLIPR assay	ec50	0.0007	uM
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[2-[3-[2-[2-(3-aminopropoxy)ethoxy]ethoxy]propylamino]-2-oxoethoxy]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]-methylamino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide	1446044: Agonist activity at human NMUR2 expressed in CHO cells assessed as induction of Ca2+ flux measured for 180 secs by Fluo 4-AM dye-based FLIPR assay	ec50	0.0007	uM
(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide	1352034: Agonist activity at human NMUR2 expressed in HEK293 cells assessed as induction of IP3 levels using myo-[2-3H(N)]-inositol after 60 mins by SPA-based topcount assay	ec50	0.0007	uM
(4S)-5-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[(2S)-2-[[(2S)-5-carbamimidamido-1-[[(2S)-1,4-diamino-1,4-dioxobutan-2-yl]amino]-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-3-hydroxy-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-3-carboxypropanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoic acid	1273140: Agonist activity at recombinant human NMU2 expressed in HEK293 cells assessed as change in intracellular calcium flux by fluorescence assay	ec50	0.0008	uM
(2S)-5-[3-[2-[2-[3-[[2-[2-[[(2S)-1-[[1-[[(2S)-1-[[1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(1S)-3-amino-1-carboxy-3-oxopropyl]amino]-5-[(N’-methylcarbamimidoyl)amino]-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-methyl-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-2-oxoethoxy]acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-2-[[4-[(hexadecanoylamino)methyl]cyclohexanecarbonyl]amino]-5-oxopentanoic acid	1464657: Agonist activity at human NMUR2 expressed in CHO cells assessed as increase in intracellular calcium influx after 180 secs by Fluo 4-AM dye based FLIPR assay	ec50	0.0008	uM
(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-(3-aminopropanoylamino)-3-(4-hydroxyphenyl)propanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]-4-methylpentanoyl]amino]-3-pyridin-4-ylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide	1446044: Agonist activity at human NMUR2 expressed in CHO cells assessed as induction of Ca2+ flux measured for 180 secs by Fluo 4-AM dye-based FLIPR assay	ec50	0.0008	uM
(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxy-2,6-dimethylphenyl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide	1352034: Agonist activity at human NMUR2 expressed in HEK293 cells assessed as induction of IP3 levels using myo-[2-3H(N)]-inositol after 60 mins by SPA-based topcount assay	ec50	0.0008	uM
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-(6-aminohexanoylamino)-3-(4-hydroxyphenyl)propanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]-methylamino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide	1446044: Agonist activity at human NMUR2 expressed in CHO cells assessed as induction of Ca2+ flux measured for 180 secs by Fluo 4-AM dye-based FLIPR assay	ec50	0.0008	uM
(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-(3-aminopropanoylamino)-3-(4-hydroxyphenyl)propanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-5-oxopentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide	1446044: Agonist activity at human NMUR2 expressed in CHO cells assessed as induction of Ca2+ flux measured for 180 secs by Fluo 4-AM dye-based FLIPR assay	ec50	0.0009	uM
(4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1,4-diamino-1,4-dioxobutan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]-methylamino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-3-(4-hydroxyphenyl)-2-[(2-piperazin-1-ylacetyl)amino]propanoyl]amino]-5-oxopentanoic acid	1446044: Agonist activity at human NMUR2 expressed in CHO cells assessed as induction of Ca2+ flux measured for 180 secs by Fluo 4-AM dye-based FLIPR assay	ec50	0.0009	uM
(4S)-4-[[(2S)-2-(3-aminopropanoylamino)-3-(4-hydroxyphenyl)propanoyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S)-1,4-diamino-1,4-dioxobutan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-oxopentanoic acid	1446044: Agonist activity at human NMUR2 expressed in CHO cells assessed as induction of Ca2+ flux measured for 180 secs by Fluo 4-AM dye-based FLIPR assay	ec50	0.0012	uM
(4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(2S)-1,4-diamino-1,4-dioxobutan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-3-(4-hydroxyphenyl)-2-[(2-piperazin-1-ylacetyl)amino]propanoyl]amino]-5-oxopentanoic acid	1446044: Agonist activity at human NMUR2 expressed in CHO cells assessed as induction of Ca2+ flux measured for 180 secs by Fluo 4-AM dye-based FLIPR assay	ec50	0.0014	uM
(2S)-5-[3-[2-[2-[3-[[2-[2-[[(2S)-1-[[1-[[(2S)-1-[[1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(1S)-3-amino-1-carboxy-3-oxopropyl]amino]-5-[(N’-methylcarbamimidoyl)amino]-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-methyl-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-2-oxoethoxy]acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-2-[[4-[(octadecanoylamino)methyl]cyclohexanecarbonyl]amino]-5-oxopentanoic acid	1464657: Agonist activity at human NMUR2 expressed in CHO cells assessed as increase in intracellular calcium influx after 180 secs by Fluo 4-AM dye based FLIPR assay	ec50	0.0015	uM
(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-naphthalen-2-ylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide	1352034: Agonist activity at human NMUR2 expressed in HEK293 cells assessed as induction of IP3 levels using myo-[2-3H(N)]-inositol after 60 mins by SPA-based topcount assay	ec50	0.0016	uM
(2S)-5-[3-[2-[2-[3-[[2-[2-[[(2S)-1-[[1-[[(2S)-1-[[1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(1S)-3-amino-1-carboxy-3-oxopropyl]amino]-5-[(N’-methylcarbamimidoyl)amino]-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-methyl-1-oxo-3-phenylpropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-2-oxoethoxy]acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-2-[[4-[(dodecanoylamino)methyl]cyclohexanecarbonyl]amino]-5-oxopentanoic acid	1464657: Agonist activity at human NMUR2 expressed in CHO cells assessed as increase in intracellular calcium influx after 180 secs by Fluo 4-AM dye based FLIPR assay	ec50	0.0018	uM
(2S)-2-[[(2S)-2-[[(2S,3aS,7aS)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide	1352034: Agonist activity at human NMUR2 expressed in HEK293 cells assessed as induction of IP3 levels using myo-[2-3H(N)]-inositol after 60 mins by SPA-based topcount assay	ec50	0.0018	uM
(2S)-5-[3-[2-[2-[3-[[2-[2-[[(2S)-1-[[1-[[(2S)-1-[[1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(1S)-3-amino-1-carboxy-3-oxopropyl]amino]-5-[(N’-methylcarbamimidoyl)amino]-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-cyclohexyl-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-2-oxoethoxy]acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-2-[[4-[(octadecanoylamino)methyl]cyclohexanecarbonyl]amino]-5-oxopentanoic acid	1464657: Agonist activity at human NMUR2 expressed in CHO cells assessed as increase in intracellular calcium influx after 180 secs by Fluo 4-AM dye based FLIPR assay	ec50	0.0019	uM
(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-1-[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[2-[3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(hexadecanoylamino)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoylamino]-2-methylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]amino]butanediamide	1273140: Agonist activity at recombinant human NMU2 expressed in HEK293 cells assessed as change in intracellular calcium flux by fluorescence assay	ec50	0.0019	uM
(2S)-5-[3-[2-[2-[3-[[2-[2-[[(2S)-1-[[1-[[(2S)-1-[[1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(1S)-3-amino-1-carboxy-3-oxopropyl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-cyclohexyl-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-2-oxoethoxy]acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-2-[[4-[(octadecanoylamino)methyl]cyclohexanecarbonyl]amino]-5-oxopentanoic acid	1464657: Agonist activity at human NMUR2 expressed in CHO cells assessed as increase in intracellular calcium influx after 180 secs by Fluo 4-AM dye based FLIPR assay	ec50	0.0020	uM
(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-(3-cyclohexylpropanoylamino)-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]butanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide	1659724: Agonist activity at human NMUR2 expressed in CHO cells by Fluo-4-AM dye based calcium mobilization assay	ec50	0.0022	uM
(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-1-[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-3-(4-fluorophenyl)-2-[[(2S)-3-(1H-indol-3-yl)-2-[(2-thiophen-2-ylacetyl)amino]propanoyl]amino]propanoyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]amino]butanediamide	1205846: Agonist activity at human NMUR2 expressed in CHO cells assessed as intracellular calcium flux at by Fluo-4 AM dye based fluorometric imaging method	ec50	0.0026	uM
(2S)-5-[3-[2-[2-[3-[[2-[2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S)-1-[[(1S)-3-amino-1-carboxy-3-oxopropyl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-2-oxoethoxy]acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-2-[[4-[(hexadecanoylamino)methyl]cyclohexanecarbonyl]amino]-5-oxopentanoic acid	1464657: Agonist activity at human NMUR2 expressed in CHO cells assessed as increase in intracellular calcium influx after 180 secs by Fluo 4-AM dye based FLIPR assay	ec50	0.0030	uM
(2S)-4-amino-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[2-(4-hexadecylpiperazin-1-yl)acetyl]amino]propanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]-5-carbamimidamidopentanoyl]amino]-4-oxobutanoic acid	1464657: Agonist activity at human NMUR2 expressed in CHO cells assessed as increase in intracellular calcium influx after 180 secs by Fluo 4-AM dye based FLIPR assay	ec50	0.0033	uM
(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-6-aminohexanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide	1446044: Agonist activity at human NMUR2 expressed in CHO cells assessed as induction of Ca2+ flux measured for 180 secs by Fluo 4-AM dye-based FLIPR assay	ec50	0.0034	uM
(2S)-4-amino-2-[[(2S)-5-carbamimidamido-2-[[(2S)-1-[(2S)-5-carbamimidamido-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-5-carbamimidamido-2-[[(2S)-2-[[2-(4-hexadecylpiperazin-1-yl)acetyl]amino]-3-hydroxypropanoyl]amino]pentanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]amino]-4-oxobutanoic acid	1464657: Agonist activity at human NMUR2 expressed in CHO cells assessed as increase in intracellular calcium influx after 180 secs by Fluo 4-AM dye based FLIPR assay	ec50	0.0035	uM
(2S)-2-[[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-1-[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(3S)-7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carbonyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]amino]butanediamide	1352034: Agonist activity at human NMUR2 expressed in HEK293 cells assessed as induction of IP3 levels using myo-[2-3H(N)]-inositol after 60 mins by SPA-based topcount assay	ec50	0.0035	uM
(2S)-4-amino-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[2-(4-hexadecylpiperazin-1-yl)acetyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]acetyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]-5-carbamimidamidopentanoyl]amino]-4-oxobutanoic acid	1464657: Agonist activity at human NMUR2 expressed in CHO cells assessed as increase in intracellular calcium influx after 180 secs by Fluo 4-AM dye based FLIPR assay	ec50	0.0036	uM
(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-3-amino-2-[[(2S)-2-[[(2S)-2-(3-cyclohexylpropanoylamino)-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide	1352034: Agonist activity at human NMUR2 expressed in HEK293 cells assessed as induction of IP3 levels using myo-[2-3H(N)]-inositol after 60 mins by SPA-based topcount assay	ec50	0.0038	uM
(2S)-4-amino-2-[[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-1-[(2S)-5-(diaminomethylideneamino)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[3-[2-[2-[2-[2-[3-[2-[2-[2-[2-(hexadecanoylamino)ethoxy]ethoxy]ethoxy]ethoxy]propanoylamino]ethoxy]ethoxy]ethoxy]ethoxy]propanoylamino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]amino]-4-oxobutanoic acid	1464657: Agonist activity at human NMUR2 expressed in CHO cells assessed as increase in intracellular calcium influx after 180 secs by Fluo 4-AM dye based FLIPR assay	ec50	0.0038	uM
(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-acetamido-3-(4-hydroxyphenyl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]-3,4-dihydro-1H-naphthalene-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]butanediamide	1355079: Agonist activity at human NMUR2 expressed in HEK293 cells assessed as IP3 accumulation after 60 mins in presence of myo-[2-3H(N)]inositol by scintillation proximity assay	ec50	0.0038	uM

CTD chemical–gene interactions

7 total (human), top 7 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	increases mutagenesis, decreases methylation, increases methylation	2
pirinixic acid	decreases expression, increases activity, affects binding	1
sodium arsenite	increases expression	1
CGP 52608	affects binding, increases reaction	1
2-palmitoylglycerol	increases expression	1
Synephrine	increases activity	1
Tobacco Smoke Pollution	increases expression	1

ChEMBL screening assays

46 unique, capped per target: 33 functional, 8 binding, 5 admet

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1107819	Binding	Binding affinity to NMUR2	Discovery of benzhydrylpiperazine derivatives as CB1 receptor inverse agonists via privileged structure-based approach. — Eur J Med Chem
CHEMBL3362245	Functional	Agonist activity at human NMUR2 expressed in HEK293 cells at 1 to 100 nM by calcium mobilization assay relative to NMU	Discovery of selective hexapeptide agonists to human neuromedin U receptors types 1 and 2. — J Med Chem
CHEMBL4727273	ADMET	Agonist activity at human NMUR2 expressed in CHO cells at 10 nM by calcium mobilization assay	Design and synthesis of peptidic partial agonists of human neuromedin U receptor 1 with enhanced serum stability. — Bioorg Med Chem Lett

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_H377	293T/NMU2	Transformed cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.